Sells thrombectomy devices that remove blood clots from vessels throughout the body to specialist physicians and other healthcare providers.
10-K for FY2025, filed Feb 25, 2026Penumbra, the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical…View ↗
The Indigo System is designed for continuous or modulated power aspiration of thrombus in the body, leveraging the success of the Penumbra…View ↗
Our Penumbra System brand of products offers a form of mechanical thrombectomy used by specialist physicians to revascularize blood vessels…View ↗
Healthcare providers and distributors buy medical devices, with sales tied to shipment or customer receipt; hospitals use and are charged for consigned coils in procedures. In China, a partner pays fixed amounts for licensed technology and regulatory support, plus royalties on some product sales.
10-K for FY2025, filed Feb 25, 2026Delivery of products - The Company’s contracts with customers, other than the China licensing arrangements described below, typically…View ↗
Revenue is primarily comprised of product revenue net of returns, discounts, administration fees and sales rebates. Under ASC 606, the…View ↗
We license the technology to certain of our products to our existing distribution partner in China pursuant to a series of licensing…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$1.4B
10-K for FY2025, filed Feb 25, 2026
$1.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Thrombectomy
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
68%
FY2022: 60%
|
Thrombectomy, FY2025
$947.9M Sources
|
Sold outright |
|
Embolization and Other
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
32%
FY2022: 40%
|
Embolization and Other, FY2025
$455.7M Sources
|
Sold outright |
Penumbra sells directly to healthcare providers in the United States, most of Europe, Canada, Australia and Singapore; in other international markets it uses distributors. Specialist physicians use the products and influence purchasing decisions in hospitals and other healthcare settings.
10-K for FY2025, filed Feb 25, 2026We sell our products directly in the United States, most of Europe, Canada, Australia and Singapore, subject to required regulatory…View ↗
We currently sell our products in the United States through our dedicated salesforce. Our sales representatives and sales managers…View ↗
In addition to our direct sales organizations, we work with distributors in certain geographic areas where we have determined that selling…View ↗
Yes. It kept 13 cents of every revenue dollar as net income in FY2025 and turned 12 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
Growing. Revenue grew 88% in 4 years, from $747.6M in FY2021 to $1.4B in FY2025, about 17% a year.
Exited immersive healthcare
The older report describes immersive healthcare products for rehabilitation and mental well-being; the latest says Penumbra wound down the business and permanently ceased selling those products.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 25, 2026Penumbra is a global healthcare company focused on innovative therapies. We design, develop, manufacture and market novel products and have…View ↗
We concentrate on improving treatment outcomes for patients with certain forms of vascular disease and strive to improve the long-term…View ↗
The Immersive Healthcare MarketView ↗
During the year ended December 31, 2024, we made the strategic decision to wind down and exit our immersive healthcare business, and as a…View ↗
Competes with Boston Scientific, Medtronic, Stryker, Inari Medical, and Terumo
10-K for FY2025, filed Feb 25, 2026The medical device industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and…View ↗
Loading...